Clinical Trials Study

Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma

Jennifer Wu, Merly Contratto, Krishna P Shanbhogue, Gulam A Manji, Bert H O’Neil, Anne Noonan, Robert Tudor, Ray Lee

ORCID number: Jennifer Wu (0000-0002-1714-0021); Merly Contratto (0000-0003-0528-0788); Krishna P Shanbhogue (0000-0002-7071-6077); Gulam A Manji (0000-0001-9817-2414); Bert H O’Neil (0000-0001-7032-7453); Anne Noonan (0000-0001-8083-8492); Robert Tudor (0000-0002-2046-6015); Ray Lee (0000-0002-9781-9199).

Author contributions: Wu J provided comments on the final version of the phase 1b of the study; Contratto M provided the abstract, conclusion, references and completed the final revision; Lee R provided the concept, the outline, designed the study, and the major references for this manuscript; Shanbhogue KP provided analysis of all imaging studies, set up the DCE protocol (including attending the initial protocol meeting), supervised and analyzed the perfusion MRI scans, and provided comments on the results of the manuscript and revision approval; Manji GA, O’Noeal BH, Noonan A and Tudor R provided some data regarding the patients’ information that were enrolled in their facilities.

Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of New York University School of Medicine.

Clinical trial registration statement: This registration policy applies to prospective trials only.

Jennifer Wu, Merly Contratto, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, United States

Krishna P Shanbhogue, Department of Radiology at New York University School of Medicine, New York, NY 10016, United States

Gulam A Manji, Division of Hematology and Oncology, Columbia University Medical Center, New York, NY 10032, United States

Bert H O’Neil, Division of Hematology and Oncology, Indiana University, Indianapolis, IN 46202, United States

Anne Noonan, Division of Hematology and Oncology, Ohio State University Medical Center, Columbus, OH 43210, United States

Robert Tudor, Roche Pharmaceutical Company, New York, NY 10016, United States

Ray Lee, Roche and Teclison Pharmaceutical Company, Montclair, NJ 07042, United States

Corresponding author: Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org

Telephone: +1-212-2636530
Fax: +1-212-2638210

Abstract

BACKGROUND
Hypoxia-inducible factor 1α (HIF-1α) is a gene that regulates tumor survival, neovascularization and invasion. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma (HCC). RO7070179 is a HIF-1α inhibitor that decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in HCC.

AIM
To evaluate safety and preliminary activity of RO7070179 in patients with previously treated HCC, with focus on a patient with prolonged response to RO7070179.

METHODS
In the preclinical study of RO7070179 in a HCC xenograft model, the mice were
Hypoxia-inducible factor 1α (HIF-1α) is a transcription factor that mediates adaptive responses to changes in tissue oxygenation. HIF-1α regulates genes that encode proteins controlling tumor metabolism, pH, neovascularization, drug resistance, invasion, autophagy, and cell survival[1,2]. Overexpression of HIF-1α protein has been found in multiple malignant tumors including hepatocellular carcinoma (HCC). Significant association between HIF-1α overexpression and patient mortality has been shown in HCC[3]. HCC indicates a strong unmet medical need, as sorafenib had been shown in HCC to improve survival[4]. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma (HCC) patients. HIF-1α inhibitor decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in HCC.

INTRODUCTION

Hypoxia-inducible factor 1α (HIF-1α) is a transcription factor that mediates adaptive responses to changes in tissue oxygenation. HIF-1α regulates genes that encode proteins controlling tumor metabolism, pH, neovascularization, drug resistance, invasion, autophagy, and cell survival[1,2]. Overexpression of HIF-1α protein has been found in multiple malignant tumors including hepatocellular carcinoma (HCC). Significant association between HIF-1α overexpression and patient mortality has been shown in HCC[3]. HCC indicates a strong unmet medical need, as sorafenib had been the only approved medication for 10 years from 2007-2017[4]. Overexpression of HIF-1α could be one of the mechanisms for resistance. Targeting HIF-1α can be a useful approach in HCC.

Preclinical evaluation of RO7070179 in orthotopic HCC xenograft model showed no significant differences in HCC tumor weight between the 3 and 10 mg/kg groups. However, dose of 10 mg/kg of RO7070179, has shown 76% reduction of the amount of HIF-1α mRNA in HCC tissue. In the phase 1b study of RO7070179 in previously treated HCC patients, 8 out of 9 were evaluable: 1 achieved PR and 1 SD. The patient with PR responded after 2 cycles treatments, which has been maintained for 12 cycles. This patient also showed reduction in perfusion of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) after 1 cycle of treatment. After 1 cycle of treatment, both patients with PR and SD showed decrease in HIF-1α mRNA at the root of biopsies (each biopsy was divided into 2 specimens, the tip and the root).

CONCLUSION

RO7070179 can reduce HIF-1α mRNA level in HCC patients with SD or PR. It is well tolerated at 10 mg/kg, with transaminitis as the dose of increased toxicity. This study indicates that RO7070179 might benefit HCC patients, and an early signal for clinical benefit can potentially be predicted through changes in either mRNA level or DCE-MRI within 1 cycle of therapy.

Key words: Hepatocellular carcinoma; Hypoxia-inducible factor 1α; RO7070179, Supercresponder; Dynamic contrast-enhanced-magnetic resonance imaging

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Overexpression of hypoxia-inducible factor 1α (HIF-1α) correlates with poor prognosis in hepatocellular carcinoma (HCC) patients. HIF-1α inhibitor decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in HCC.
in patients with various solid tumors leads to an inconsistent result among the down-regulation of HIF-1α mRNA, HIF-1α protein, mRNAs of several HIF-1α target genes and tumor perfusion. This study is designed to focus on one single type of tumor HCC for a reevaluation RO7070179’s target and downstream effectors, based on the rationale that liver is one of the organs with the most abundant RO7070179 accumulation. Various translational endpoints were designed to study the mechanism including HIF-1α mRNA levels, protein levels of key HIF-1α targets, angiogenesis, tumor perfusion and therapeutic efficacy after 1 cycle of treatment with RO7070179.

MATERIALS AND METHODS

Preclinical study design of testing RO7070179 in a HCC xenograft model

Hep3B HCC cells were used to inject orthotopically into the liver of SCID-beige mice. Without treatment, nearly all mice died in 8 wk. Two weeks after Hep3B tumor cells were implanted, mice were separated into 4 groups (10 mice for each group) and received RO7070179 subcutaneous injection at doses of 0, 3, 10 and 30 mg/kg for a total of 10 doses (days 0, 1, 2, 3, 7, 10, 17, 21 and 24.5). All mice were harvested at 6th weeks after HCC implantation for analysis. Tumor and normal liver were weighted, and then RNA extracted for examination of HIF-1α mRNA by qRT-PCR (Taqman) and tissue RO7070179 oligo levels. Other analysis of the liver and tumor specimens include genome-wide microarrays, proteins with IHC, angiogenesis with CD31 staining, Ki67, tumor apoptosis marker Casp-3.

Analysis of the HIF1α mRNA

The AllPrep DNA/RNA/miRNA universal kits were used for preparation of RNA. First, 250 ng of total RNA was prepped using the high capacity cDNA reverse transcription kit (Life Technologies) and final product normalized to 100 µL. Among them, 4 µL was used for qPCR by the TaqMan gene expression assay (Life Technologies) specific to HIF1α transcripts and a panel of 4 endogenous controls (GAPDH, UBE2D2, SFRS4 and CTBP1). To analyze the relative expression level of HIF-1α, the mean Ct value (Ct - cycle threshold, is a DNA quantification measurement in real time PCR that contains the number of cycles where the fluorescence surpasses the threshold of background level) of each gene expression assay was determined from 3 replicates. The linear range of Ct values was determined by the validation method. Delta Ct of HIF1α and the geometric mean of endogenous controls were calculated. The Delta Ct of each specimen and a Universal Human Reference RNA (UHRR) were used to determine the relative expression level of HIF-1α (Delta Ct) of each specimen.

Immunohistochemistry analysis

Immunohistochemistry (IHC) was performed per standard procedures using the following antibodies; HIF-1α (Cat#LS-C177574, from LS Bio); HIF-2α (#PA1-16510, Thermo); VEGF (#ab52917, Abcam); CD31 (#ab28364, Abcam); Ki67 (#VP-RM04, Vector); cleaved Caspase 3-Asp175 (#9664s, Cell Signaling).

Analysis of the RO7070179 oligo levels

The quantification of the oligo levels of RO7070179 is conducted with a hybridization-ELISA procedure for the determination of RO7070179. The method involves hybridization of the antisense oligonucleotide (containing phosphorothioate modifications in its backbone and LNA modification to some of its sugar moieties) to complementary oligonucleotide probes, one (capture probe) complementary to the 5’-half of the RO7070179 molecule, and one detection probe complementary to the 3’-half of the molecule. The capture probe is conjugated with biotin which mediates non-covalently binding to the surface of a Reacti-Bind Neutravidin coated black plate, whereas the detection probe is conjugated with digoxigenin. Measurement of the surface bound analyte is accomplished by the addition of a Fab-fragment of an antibody directed against digoxigenin. This Fab-fragment is coupled to an alkaline phosphatase which converts AttoPhos® to a fluorescent product that is directly related to the amount of bound RO7070179.

Clinical study for the proof of mechanism

A phase 1b clinical trial was also conducted in 6 sites. Patients with advanced HCC who fulfill the criteria of HCC diagnosis according to the American Association for the Study of Liver Disease criteria and have failed at least one line of systemic therapy were enrolled. Other key eligibility criteria include Child-Pugh score A, ECOG 0-1, adequate organ function with liver function AST/ALT no higher than 3 X upper limit of normal (ULN) and platelet above 60000/µL, bilirubin and creatinine no higher than
2 X ULN. RO7070179 was administered as a 2-h weekly IV infusion in 6-wk cycles after two loading doses of 13 mg/kg RO7070179 administered on Days 1 and 4 in Week 1 of Cycle 1. If unacceptable toxicities were observed in 30% of existing patients, subsequent patients would have a dose reduction to 10 mg/kg weekly or 6 mg/kg if still not tolerable.

Extensive translational analyses were included in for the study. All patients should have a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to analyze the tumor perfusion in baseline and 1 cycle after treatment to evaluate tumor perfusion using $K_{trans}$ and other parameters. The result of DCE-MRI is used to select a region in tumor for biopsy in baseline. The region selected correlates to no evidence of necrosis and relatively lower blood flow, hence potentially higher HIF-1α expression. Patients also had a second biopsy after 1 cycle of treatment at the same site for comparison. Clinical efficacy was assessed by contrast CT every 3 mo until progression or death. The biopsy was targeted to have a core of 20 mm in length, with tips of both ends saved in cryovials for RNA extraction, and the next 6 mm for fixation in 10% formalin for histology examination and IHC. The remaining specimens were snap frozen for measuring of drug levels as part of the tumor PK analysis.

**RESULTS**

*Preclinical evaluation of the RO7070179 in orthotopic HCC xenograft model*

Four groups of mice were treated with RO7070179 at the doses of 0, 3, 10 and 30 mg/kg for total 10 doses. Mice in the group that received the highest dose at 30 mg/kg/dose failed to tolerate treatment with 2 deaths at day 6, 2 deaths at day 7 and 3 deaths at day 8. The remaining 3 mice of this group were then sacrificed ahead of schedule on day 9. The liver enzymes AST/ALT/ALP (alkaline phosphatase) of these 3 mice all showed significant elevation above 800, consistent with hepatotoxicity from the study medication. Mice in the remaining 3 groups were sacrificed at the scheduled time at 1 cycle. AST/ALT in blood of mice receiving 3 and 10 mg/kg RO7070179 also revealed a dose-dependent increase, consistent with RO7070179-related liver toxicity. Liver in the three remaining groups were dissected first and compared in weights. The weights of the control and those receiving 3 mg/kg RO7070179 showed no difference, but that receiving 10 mg/kg had a statistical increase compared with the other two groups, which is potentially related to a compensatory proliferation due to hepatotoxicity. Liver tumors were then dissected and weighted, and no statistical difference was observed.

*Pharmacokinetics of the RO7070719*

Concentrations of RO7070719 in plasma, tumor and healthy liver followed dose-linear kinetics over this dose range. The mean accumulated liver concentrations were 9.92, 27.1 and 66.6 µg/g tissue at the 3, 10, and 30 mg/kg/administration, respectively (Figure 1A). The mean concentration in tumors was 2.38 and 11.5 µg/g tissue at 3.0 and 10.0 mg/kg/administration, respectively, indicating that tumors were less exposed to RO7070179 than normal liver tissue (Figure 1B).

*Down-regulation of HIF-1α mRNA and its downstream effectors after RO7070179 treatment*

Based on the TaqMan qPCR analysis of HIF-1α mRNA (the primary target of RO7070179) in normal liver, the groups received 3 and 10 mg/kg achieved 82% and 84%, decreases in the HIF1α mRNA level when compared to that of the control group (Figure 1C). When compared to control in the orthotopic tumor the levels of HIF-1α mRNA showed a 53% decrease in the group of 3 mg/kg compared to control, and a 76% of decrease in the group of 10 mg/kg (Figure 1D). This result support the target engagement of RO7070179 in both normal liver and orthotopic tumor, and normal liver is more sensitive to RO7070179 than the orthotopic tumor.

*Downstream effector of HIF-1α mRNA*

Immunohistochemical analysis was conducted in tumor to examine the protein levels of HIF-1α and its downstream effector VEGF, apoptosis marker activated Caspase 3 as shown in Figure 2. The levels of HIF-1α showed a barely visible decrease in protein level in the group receiving 3 mg/kg RO7070179, and an obvious decrease in the group receiving 10 mg/kg RO7070179, which is consistent with the HIF-1α mRNA decrease of 53% and 76%, respectively. Similarly, minimal change was noticed in the levels of VEGF and activated Caspase 3 in the tumor treated with 3 mg/kg; whereas an obvious decrease in VEGF and an increase of activated Caspase 3 were observed in
Figure 1 Concentrations of RO7070719 in normal mouse liver, Hep3B orthotopic tumor and specimens harvested at Day 39. A: Concentrations of RO7070719 in normal liver; B, C: Hep3B tumor xenograft and the levels of HIF-1α mRNA in (C) normal liver; D: Hep3B tumor xenograft. Normal mouse liver (A) and Hep3B orthotopic tumor (B) specimens harvested at Day 39 (n = 10/group, except at 30 mg/kg n = 3/group harvested at Day 23) were quantified using hybridization-ELISA for RO7070719 concentrations. The levels of HIF-1α mRNA were quantified by qPCR in normal liver (C), and Hep3B orthotopic tumor xenografts (D).

tumors treated with 10 mg/kg, which is consistent with those of the HIF-1α mRNA. These results indicate that the biological effect of HIF-1α decrease can be further extended to VEGF and eventually to an induction of caspase cascade. We created the biomarker analysis flow chart to illustrate the mechanism of action of HIF-1α inhibitors in HCC (Figure 3).

The positive animal study prompted a clinical trial to investigate the activity of RO7070179 in HCC patients who have failed at least one line of systemic therapy, predominately sorafenib. A total of 9 male patients were enrolled in the study with age group between 45 to 75 years. Three of 8 patients (37.5%) were below 65 years and the remaining 5 patients (62.5%) were more than 65 years, the median age was 69 years. Two of 8 patients (25.0%) were Asian, 3 of 8 patients (37.5%) were Black or African American and 3 of 8 patients (37.5%) were white. Two of 8 patients (25.0%) were from Hispanic or Latino origin, while six of 8 patients (75.0%) were from non-Hispanic or Latino origin. The median weight (kg) of patients at baseline was 71.95. The minimum and maximum weight of patients enrolled for study was 56.7 and 111.3 respectively. The median height (cm) of patients at baseline was 170. The minimum and maximum height of patients enrolled for study was 161 and 179 respectively. The median BMI (kg/m²) of patients at baseline was 26.68. The minimum and maximum BMI (kg/m²) of patients enrolled for study was 19.2 and 39.9 respectively.

**Side effects**

The study started with a dose at 13 mg/kg IV at days 1 and 4 in week 1 for loading, followed by 13 mg/kg weekly afterwards. The dose was reduced to 10 mg/kg afterwards due to observation of increased toxicity in 3 of the first 6 patients. The toxicity of RO7070179 was considered related to drug accumulation in liver, and HCC patients have less liver reserve compared to those with other malignancies tested in prior phase I studies. Subsequently dose was reduced to 10 mg/kg weekly and it was well tolerated in the next 3 patients.

The most common adverse events (AEs) were ALT increased (5 patients, 55.6%), AST increased (5 patients, 55.6%), blood creatinine increased (4 patients, 44.4%), fatigue (4 patients, 44.4%), chills (3 patients, 33.3%) and decreased appetite (3 patients, 33.3%). The most common grade 3 or 4 AEs were ALT increased (4 patients, 44.4%) and AST increased (4 patients, 44.4%).

**Efficacy**

Only 3 of the 9 patients were able to complete 2 cycles of treatments and had efficacy
evaluation by a follow-up CT scan (Figure 4). One patient, who had a prior surgical resection and recurred in the surgical margin with metastatic to lung, had a robust efficacy. The pretreatment liver lesion was as large as 6.7 cm in size with multiple lung metastasis. With 2 cycles of treatments, this patient achieved PR by mRECIST criteria, and the lesion in liver decreased to 3.7 cm along with reduction in size and number of lung lesions. As of today, this patient has completed the study (12 cycles) and stayed in PR as of May 14, 2018 of CT scan. The lung lesions complete disappeared and liver lesion down to 2.3 cm without contrast enhancement. Two other patients also completed 2 and 4 cycles, respectively. One had SD and one with PD at the first assessment post cycle 2.

**Biomarker analysis of the super-responder**

The mRNA of HIF-1α was first examined by qPCR. Specimens 1 are the tumor specimens located at the tip of the biopsy cores and specimens 2 are those at the other end of biopsy, called root so that different locations of biopsies can be investigated to detect any potential spatial heterogeneity. The results are shown in Table 2. Unfortunately, no definitive trend can be detected for either specimens 1 or 2, or before and after RO7070179 treatment. This suggests a significant temporal and spatial relationship exist in tumor.

As of safety cut-off date, 28 Feb 2017, efficacy data is represented as “spaghetti plots” for HIF-1α in specimens obtained prior to the administration (screening) of the HIF-1α inhibitor and after cycle 1 of (6 wk) treatment. Dots represent individual specimens; lines connect specimens from individual patients taken at consecutive time interval. Expression is shown as the difference in the cycle threshold (Ct) value between the HIF-1α gene and the mean Ct of the reference genes, higher values correspond to stronger expression.

**Table 2** shows gene expression as delta Ct value of specimen 01 in patient. The super-responder patient was observed with lower delta Ct value as compared at screening corresponding to up regulation expression of gene as compared at screening. It showed down regulation of HIF-1α gene.
**Analysis of tumor perfusion by DCE-MRI**

The DEC-MRI scans of the patient who achieved durable PR were examined in details. Figure 5 shows the heat map of the perfusion scan in liver and tumor before (Figure 5A) and after the first cycle of treatment (Figure 5B), and a clear reduction was demonstrated after treatment. The $K_{\text{trans}}$, a parameter representing perfusion, was calculated in tumor as shown in Table 3.

**DISCUSSION**

**Preclinical study**

High level of HIF-1α mRNA indicates poor prognosis in HCC\(^{[9,10]}\). During hypoxia, HIF-1α does not go through degradation by enzyme prolyl hydroxylase, instead it is stabilized and accumulated in the nucleus. HIF-1α then activates the transcription of target genes such as vascular endothelial growth factor (VEGF) that contributes angiogenesis. In addition, it stimulates transcriptions of growth factors such as insulin-like growth factor-2 and transforming growth factor-α that lead to cell proliferation. It also induces epithelial-mesenchymal transition by inhibiting E-Cadherin, which maintains the epithelial integrity, thus stimulates tumor invasion. HIF-1α therefore leads to neovascularization, proliferation, and metastasis in various tumors, including HCC\(^{[11]}\). RO7070179, a HIF-1α inhibitor has been studied in HCC xenograft models and later on in HCC patients.

**Liver toxicity is dose dependent**

In the orthotopic HCC mice model, the absorption of RO7070179 is higher in normal liver compared to HCC tissue. Therefore, after treatment with RO7070179, the level of HIF-1α mRNA (the target of RO7070179 inhibition) is lower in normal liver than in HCC. In order to achieve adequate reduction of HIF-1α protein or mRNA level in HCC, a high dose of RO7070179 is required. This was illustrated in the preclinical study using orthotopic HCC xenograft mice. The groups that received 3 and 10 mg/kg exhibited dose dependent-increase of AST/ALT level, while the highest dose of 30 mg/kg led to liver toxicity (7 out of 10 mice died, and the remaining had excessively high level of the AST/ALT beyond 800).

No difference in HCC tumor weights were shown between the two groups, indicating that the lower dose (3 mg/kg) had produced similar tumor volume reduction compared to the higher dose (10 mg/kg). Liver toxicities were explained by the pharmacokinetics (PK) data, which showed that RO7070179 achieved a higher concentration in normal liver than the tumor, in a dose dependent manner.

**Downstream targets indicate that 10 mg/kg is the optimal dose of RO7070179**

At a dose of 10 mg/kg, RO7070179 decreased the level of HIF-1α mRNA by 76%, which was sufficient to reduce the protein level of HIF-1α and the downstream target VEGF of HIF-1α and induction of apoptosis (shown by activated caspase 3) (Figure 2).
However, at the dose of 3 mg/kg, RO7070179 was able to reduce mRNA level by 53%, but HIF-1α protein level did not change, nor was the downstream target of HIF-1α mRNA (VEGF) or apoptosis based on activated caspase 3. These findings suggest that it is necessary to suppress at least 75% of the mRNA level of HIF-1α in order to accomplish adequate inhibition of HCC tumor clinically.

**Phase 1b study**

In our phase 1b study of RO7070179 in previously treated HCC patients, the primary end point of HIF-1α mRNA level change after 1 cycle of treatment was not met, and the study was terminated early. The secondary end point of this study regarding the safety, efficacy, and pharmacokinetics of RO7070179 could not be done due to the small number of patient enrolled. However, the extra-ordinary response observed in one single patient warrant us to undergo detailed investigation of this this patient to learn any lesion from this patient. We will focus our discussion on the super-responder.

**Super-responder**

DCE-MRI changes correlate with response: This super-responder achieved PR after 2 cycles of treatment (Figure 5) and this response is still maintained after 12 cycles. The response indicates that RO7070179 induces a rapid response as early as 2 cycles which can be potentially long lasting. In consistent with the MRI tumor shrinkage, $K_{trans}$ in DCE-MRI also exhibit a significant decrease after 1 cycle treatment (Table 3). This indicated that the reduction of tissue perfusion in the tumor after 1 cycle of treatment reflected true decrease in tissue perfusion, as liver background perfusion did not change from the baseline. Reduction in tissue perfusion on DCE-MRI correlates with an early response to therapy.

Tissue perfusion and permeability correlate with PFS

In a prospective study of 31 HCC patients who were treated with sorafenib and tegafur/uracil, the progression free survival (PFS) was 29.1 wk in patients with reduction of $K_{trans} \geq 40\%$ vs 8.7 wk in patients with reduction of $K_{trans} < 40\%$. This change was demonstrated as early as 14 d on treatment[13]. The overall survival (OS) is also longer in patients with $K_{trans} \geq 40\%$ compared to patients with $K_{trans} < 40\%$ (53 wk
Table 2  Fold of changes in hypoxia inducible factor-1α mRNA by qPCR

| Number | Patient ID                  | Specimen 1 at tip site(fold changed) | Specimen 2 at root site(fold changed) |
|--------|-----------------------------|--------------------------------------|---------------------------------------|
| 1      | 2886230004 (super-responder) | 0.9†                                 | 0.19†                                 |

Specimen 1 is the tip of the biopsy, and specimen 2 is the other end of biopsy. A difference in the number of cycles was assumed to be a 2-fold difference.

†The results of the patient who had a robust clinical response in partial response.

Effects on HIF-1α mRNA and protein level vary by mechanism of action of HIF-1α inhibitors

Each HIF-1α inhibitor has a slight different mechanism of action. For instance, PX-478 works in transcriptional and translation level, causes reduction both in HIF-1α mRNA and protein level[13]. Other HIF-1α inhibitors only decrease the HIF-1α mRNA level such as GL331[14]. It works by inhibiting the target genes such as VEGF. RO7070179, an antisense oligonucleotide that also only decrease HIF-1α mRNA level with minimal effect on HIF-1α protein level. HIF-1α inhibitors can cause target gene downstream changes by inhibiting the tumor-induced angiogenesis, regardless if there is a decrease in HIF-1α mRNA alone or in both mRNA and protein level[15,16]. This also illustrates the difficulty in using HIF-1α mRNA or protein as the biomarkers for clinical prediction.

RO7070179 achieved PR in 1 out of 9 HCC patients, an early response can potentially be predicted through either mRNA level change or reduction in tissue perfusion on DCE-MRI within 1 cycle of therapy using the root of the biopsy specimen.

HIF-1α promotes tumor survival, neovascularization and tumor invasion especially in HCC. RO7070179 is an HIF-1α inhibitor that is well tolerated at 10 mg/kg, with transaminitis as the dose limiting toxicities. It reduces HIF-1α mRNA level and downstream targets, it could be a potential treatment in HCC. In a super-responder HCC patient, HIF-1α mRNA level decreased at both specimen 1 (tip of biopsy) and specimen 2 (root of biopsy) after 1 cycle (6 wk) of RO7070179 treatment. It also showed an early signal response from DCE MRI analysis by decrease of perfusion in HCC tumor after 1 cycle of treatment. In a super-responder HCC patient who achieved PR response at 2 cycle (12 wk), continued until 12 cycles. This study indicates that RO7070179 might benefit HCC patients and its response can be predicted through early 6 wk of DCE MRI and biopsy of tumor. This result will require more patients for validation.
**Table 3 The difference in $K^{\text{trans}}$ for the tumor and the liver between pre and post-treatment**

|            | Pre-treatment                  | Post-treatment               |
|------------|--------------------------------|------------------------------|
| Tumor      | $K^{\text{trans}}$ pre-treatment: $849 \times 10^{-3}$ min | $K^{\text{trans}}$ post-treatment: $122 \times 10^{-3}$ min |
| Liver (left lobe) | $K^{\text{trans}}$ pre-treatment: $245 \times 10^{-3}$ min | $K^{\text{trans}}$ post-treatment: $255 \times 10^{-3}$ min |

$K^{\text{trans}}$ is a measurement in dynamic contrast-enhanced magnetic resonance imaging to determine tissue perfusion and permeability. After 1 cycle of treatment, $K^{\text{trans}}$ in the patient with PR demonstrated decrease from baseline (Table 3) in the tumor, while $K^{\text{trans}}$ in the liver remained stable during the 2 time periods.

**Figure 5** The effect of RO7070179 in the super responder using heat maps (red means more perfusion and green means less perfusion) between the 2 time periods (baseline 6/20/16 and after 1 cycle 7/28/16). The change of color from red to green correlates with decrease in perfusion between those time periods. A: Pretreatment heat map from pretreatment perfusion magnetic resonance imaging (MRI) (Coronal Section); B: Post treatment heat map from posttreatment perfusion MRI (Coronal Section to include aorta which was used as internal standard for blood flow calibration).

**ARTICLE HIGHLIGHTS**

**Research background**

Hypoxia-inducible factor 1α (HIF-1α) is a gene that regulates tumor survival, neovascularization and invasion. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma (HCC). RO7070179 is an HIF-1α inhibitor that decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in HCC.

**Research motivation**

HIF-1α inhibitor such as RO7070179 has a potential benefit for HCC patients in the future. Eventhough, in this study there was only one super-responder HCC patients that showed PR with RO7070179. It needs validation in a large population and studies.

**Research objectives**
The purpose of this study is to evaluate safety and preliminary activity of RO7070179 in patients with previously treated HCC, with focus on a patient with prolonged response to RO7070179.

Research methods
The research methods is a prospective study in preclinical study of RO7070179 in a HCC xenograft model, the mice were separated into 4 groups with each group received doses of 0, 3, 10 and 30 mg/kg for total 10 doses. HCC patients who failed at least one line of systemic treatment, received RO7070179 as a weekly infusion, each cycle is 6 wk. We evaluated the safety and HIF-1α mRNA levels of RO7070179.

Research results
Preclinical evaluation of RO7070179 in orthotopic HCC xenograft model showed no significant differences in HCC tumor weight between the 0, 3 and 10 mg/kg groups. However, dose of 10 mg/kg of RO7070179, has shown 76% reduction of the amount of HIF-1α mRNA in HCC tissue. In the phase 1b study of RO7070179 in previously treated HCC patients, 8 out of 9 were evaluable: 1 achieved PR and 1 SD. The patient with PR responded after 2 cycles treatments, which has been maintained for 12 cycles. This patient also showed reduction in perfusion of DCE-MRI after 1 cycle of treatment. After 1 cycle of treatment, both patients with PR and SD showed decrease in HIF-1α m RNA at the root of biopsies (each biopsy was divided into 2 specimens, the tip and the root).

Research conclusions
RO7070179 can reduce HIF-1α mRNA level in HCC patients with SD or PR. It is well tolerated at 10 mg/kg, with transaminitis as the dose of increased toxicity. This study indicates that RO7070179 might benefit HCC patients, and an early signal for clinical benefit can potentially be predicted through changes in either mRNA level or DCE-MRI within 1 cycle of therapy.

Research perspectives
RO7070179 has shown encouraging activity in previously treated HCC patients, however such activity needs to be further evaluated in a phase II study with more patients.

REFERENCES

1. Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol 2005; 11: 1705-1708 [PMID: 15786555 DOI: 10.3748/wjg.v11.i11.1705]

2. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor-1. Crit Rev Oncol Hematol 2006; 59: 15-26 [PMID: 16716598 DOI: 10.1016/j.critrevonc.2005.12.003]

3. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Neeman B, Bom F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490 [PMID: 9697772 DOI: 10.1038/23667]

4. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71-103 [PMID: 10821478 DOI: 10.1080/10409230091169186]

5. Jiang BH, Agami F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-5335 [PMID: 9193757]

6. Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, Zhoa J, Zhang BH, Fan J. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009; 9: 418 [PMID: 19948069 DOI: 10.1186/1471-2407-9-418]

7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zazaem S, Bolondi L, Grete TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voltolisi D, Brux J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa070857]

8. Greenberger LM, Horak JD, Filpula D, Supra P, Westergaard M, Frenkenlund HF, Albaek C, Schroder H, Oram H. A RNA antagonist of hypoxia-inducible factor-1 alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008; 7: 3596-3608 [PMID: 18974394 DOI: 10.1158/1535-7163.MCT-08-0510]

9. Zheng SS, Chen XY, Yin X, Zhang BH. Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One 2013; 8: e65753 [PMID: 23790043 DOI: 10.1371/journal.pone.0065753]

10. Xiong XX, Qiu XY, Hu DX, Chen XQ. Advances in Hypoxia-Mediated Mechanisms in Hepatocellular Carcinoma. Mol Pharmacol 2017; 92: 246-255 [PMID: 28242743 DOI: 10.1124/mol.116.107796]

11. Cohen RB, Olszanski A, Figueroa J, Hurwitz H, Lokiec F, Rezai K, Berkowitz N, Buchbinder A. Down-modulation of mRNA by EZN-2968, an hypoxia-inducible factor-1α (HIF-1α) mRNA antagonist, administered in adult patients with advanced solid tumors. Cancer Res 2011; 71: LB-407-LB-407 [DOI: 10.1158/1535-7445.AM2011-LB-407]

12. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TT. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011; 55: 858-865 [PMID: 21338641 DOI: 10.1016/j.jphe.2011.01.032]

13. Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 2012; 49: 24-40 [PMID: 22305612 DOI: 10.1016/j.ejmech.2012.01.033]

14. Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Hsien Lee Y, Lin S. GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem Biophys Res Commun 2003; 302: 95-100 [PMID: 12593833 DOI: 10.1016/S0006-291X(03)00111-6]
15 Ding L, Chen X, Jing K, Wang H, Zhang W. Inhibition of the VEGF expression and cell growth in hepatocellular carcinoma by blocking HIF-1alpha and Smad3 binding site in VEGF promoter. *J Huazhong Univ Sci Technolog Med Sci* 2006; 26: 75-78 [PMID: 16718928 DOI: 10.1007/BF02828043]

16 Yasuda S, Ariii S, Morii A, Isobe N, Yang W, Oe H, Fujimoto A, Yonenaga Y, Sakashita H, Inamura M. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. *J Hepatol* 2004; 40: 117-123 [PMID: 14672622 DOI: 10.1016/S0168-8278(03)00503-8]

P- Reviewer: Morelli F, Ozyigit G, Zhou J
S- Editor: Ji FF
L- Editor: A
E- Editor: Wu YXJ
